Leukemia Research
Volume 27, Issue 3 , Pages 267-273 , March 2003

Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

  • Grażyna Hoser

      Affiliations

    • Department of Clinical Cytobiology, Medical Center for Postgraduate Education, 01-813 Warszawa, Marymoncka 99, Poland
    • ,
  • Ireneusz Majsterek

      Affiliations

    • Department of Molecular Genetics, University of Lodz, 90-237 Lodz, Banacha 12/16, Poland
    • ,
  • Duane L. Romana

      Affiliations

    • Center for Biotechnology, College of Science and Technology, Temple University, Bio-Life Sciences Building, Room 419, Philadelphia, PA 19122, USA
    • ,
  • Artur Slupianek

      Affiliations

    • Center for Biotechnology, College of Science and Technology, Temple University, Bio-Life Sciences Building, Room 419, Philadelphia, PA 19122, USA
    • ,
  • Janusz Blasiak

      Affiliations

    • Department of Molecular Genetics, University of Lodz, 90-237 Lodz, Banacha 12/16, Poland
    • ,
  • Tomasz Skorski

      Affiliations

    • Department of Clinical Cytobiology, Medical Center for Postgraduate Education, 01-813 Warszawa, Marymoncka 99, Poland
    • Center for Biotechnology, College of Science and Technology, Temple University, Bio-Life Sciences Building, Room 419, Philadelphia, PA 19122, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-215-204-8847; fax: +1-215-204-1009.

Received 25 November 2001 ,Accepted 24 June 2002.

References 

  1. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta. 1997;1333:F217
  2. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature. 2001;411:355
  3. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, et al.  Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988;239:775
  4. Epner DE, Koeffler HP. Molecular genetic advances in chronic myelogenous leukemia [see comments]. Ann. Int. Med. 1990;113:3
  5. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human ABL gene and from the BCR-ABL fused gene. Cell. 1986;47:277
  6. Zou X, Calame K. Signaling pathways activated by oncogenic forms of ABL tyrosine kinase. J. Biol. Chem. 1999;274:18141
  7. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic ABL proteins. Biochim. Biophys. Acta. 1997;1333:F201
  8. Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Fact. Rev. 1997;8:63
  9. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829
  10. Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gall bladder adenocarcinoma cells. Int. J Cancer. 1999;80:731
  11. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 1997;9:79
  12. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148
  13. Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, et al.  ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene. 1996;13:2225
  14. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, et al. BCR-ABL exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91:1700
  15. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood. 1998;91:2415
  16. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, et al.  Skorski T: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell. 2001;8:795
  17. Slupianek A, Hoser G, Majsterek I, Bronisz A, malecki M, Blasiak J, et al.  Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol. Cell Biol. 2002;22:4189
  18. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988;175:184
  19. Parshad R, Sanford KK. Radiation-induced chromatid breaks and deficient DNA repair in cancer predisposition. Crit. Rev. Oncol. Hematol. 2001;37:87
  20. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999;57:727
  21. Autrup H, Stoner GD. Metabolism of N-nitrosamines by cultured human and rat oesophagus. Cancer Res. 1982;42:1307
  22. Modrich P. Mechanisms and biological effects of mismatch repair. Ann. Rev. Genet. 1991;25:229
  23. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al.  Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 1996;2:561
  24. Klaude M, Eriksson S, Nygren J, Ahnstrom G. The comet assay: mechanisms and technical considerations. Mutat. Res. 1996;363:89
  25. Rojas E, Lopez MC, Valverde M. Single cell gel electrophoresis assay: methodology and applications. J. Chromatogr. B Biomed. Sci. Appl. 1999;722:225
  26. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bc, l-2-independent BCR-ABL-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 1998;16:1383
  27. Johnson BW, Cepero E, Boise LH. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. J Biol. Chem. 2000;275:31546
  28. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 1998;16:335
  29. Gloc E, Warszawski M, Mlynarski W, Stolarska M, Hoser G, Skorski T, et al. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Acta Biochim. Pol. 2002;49:121–128
  30. Blasiak J, Gloc E, Mlynarski W, Drzewoski J, Skorski T. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leuk. Res. 2002;26:1093–1096
  31. Majsterek I, Blasiak J, Mlynarski W, Hoser G, Skorski T. Does BCR/ABL-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?. Cell Biol. Int. 2002;26:363
  32. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in BCR/ABL-transformed cells. Blood. 2000;95:2118
  33. Moller P, Knudsen LE, Loft S, Wallin H. The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors. Cancer Epidemiol. Biomarkers Prev. 2000;9:1005
  34. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat. Rev. Cancer. 2002;2:351
  35. Lankinen MH, Vilpo LM, Vilpo JA. UV- and gamma-irradiation-induced DNA single-strand breaks and their repair in human blood granulocytes and lymphocytes. Mutat. Res. 1996;352:31
  36. Wang H, Zeng ZC, Bui TA, Sonoda E, Takata M, Takeda S, et al.  Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group. Oncogene. 2001;20:2212
  37. DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ, Iliakis G. DNA-dependent protein kinase stimulates an independently active, non-homologous, end-joining apparatus. Cancer Res. 2000;60:1245
  38. Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S, et al.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood. 2001;97:2084
  39. Maru Y, Bergmann E, Coin F, Egly JM, Shibuya M. TFIIH functions are altered by the P210 BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat. Res. 2001;483:83
  40. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev. 1999;13:916
  41. Zdraveski ZZ, Mello JA, Marinus MG, Essigmann JM. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 2000;7:39
  42. Kovacic P, Jacintho JD. Reproductive toxins: pervasive theme of oxidative stress and electron transfer. Curr. Med. Chem. 2001;8:863
  43. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 2000;275:24273
  44. Dierov J, Daley GQ, Carroll M. BCR-ABL alters the kinetics of DNA repair in transformed cells after DNA double strand damage. Blood. 2000;96:739a
  45. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia. 2000;14:1401
  46. Canitrot Y, Lautier D, Laurent G, Frechet M, Ahmed A, Turhan AG, et al.  Mutator phenotype of BCR-ABL transfected BaF3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 1999;18:2676

PII: S0145-2126(02)00163-7

Leukemia Research
Volume 27, Issue 3 , Pages 267-273 , March 2003

Article Tools

* Image Usage & Resolution